A biotech company is in the process of developing a new assay to measure vaccine immunogenicity in ferrets. From the ferrets randomly assigned the placebo the assay scores were observed to be: 108, 133, 134, 145, 152, 155, 169 and from the ferrets randomly assigned the vaccine the assay scores were observed to be: 115, 162, 162,168,170, 181, 199, 207. A researcher wishes to test whether vaccination causes a higher mean immunogenicity level than that from placebo administration. Proposition I: At the 5% significance level the appropriate decision could be a Type I Error. Proposition I: At the 5% significance level the appropriate decision is a Type I Error. Proposition I is true and Proposition II is false Proposition I is true and Proposition Il is true. Proposition I is false and Proposition II is false. O None of these choices are correct. Proposition I is false and Proposition I is true.